• Hospitals will spend up to 3% more on drugs in 2023, study finds

    Nonfederal hospitals' costs have hovered around $35 billion to $40 billion since 2018, and in 2023, overall prescription drug spending is expected to be about $38 billion, or a 1 percent to 3 percent increase from the prior year. 
  • How does your system manage rare disease patients? Becker's wants to hear.

    Sponsored
    Fill out this short survey here and attend our annual meeting for free.
  • Ohio Northern, Clarkson U. offer PharmD students dual track to earn MBA

    Ohio Northern University and Clarkson University have teamed up to offer pharmacy doctoral candidates an accelerated track that will allow them to simultaneously earn a master's of business administration degree — or another option — upon graduation.
  • 50% of albuterol solutions on back order

    About 1 in 2 albuterol solutions are in shortage two months after Akorn Operating Co., a Gurnee, Ill.-based drugmaker, closed. 
  • 25 numbers on drug shortages

    Drug shortages are at 10-year high so far in 2023, according to the American Society of Health-System Pharmacists.
  • New biologic effective against staph infections, early tests find

    A new bioengineered drug candidate demonstrated superior performance to a standard antibiotic at treating mice infected with Staphylococcus aureus, according to results from early testing published April 24 in Cell Host & Microbe. 
  • Eli Lilly begins new clinical trial for Mounjaro

    Eli Lilly has entered into a phase three clinical trial for its tirzepatide drug, also known as Mounjaro, to evaluate its efficacy at improving weight loss outcomes for patients experiencing obesity.
  • Irregular heartbeat pauses cancer drug trial

    In compliance with the FDA and European regulators, Foghorn Therapeutics paused research testing its investigative cancer therapy, FHD-609, the Cambridge, Mass.-based biotech company said April 24. 
  • Malnutrition, a sinking face and weird dreams: Ozempic's side effects

    Patients who take Ozempic, a diabetes medication popularized for its off-label use as a weight-loss drug, are reporting strange outcomes. 
  • UCSF pharmacy leader calls pharmacist scope efforts 'necessary and overdue'

    Desi Kotis, PharmD, the chief pharmacy executive at the University of California San Francisco Health, told Becker's hospital pharmacy teams should continue focusing on grassroots efforts to ensure patients know their pharmacists and pharmacy technicians. 
  • Mark Cuban hasn't 'f—ed up' the pharma industry yet

    Mark Cuban launched his online drug business, Mark Cuban Cost Plus Drug Co., in January 2022 with the plan to "f— up" the industry. He hasn't done that yet, he told Becker's in early April. 
  • 1 pharma trend to watch this quarter: Moody's

    The Inflation Reduction Act is spurring pharma companies into mergers and acquisitions because of the "approaching patent cliff" in 2026, according to a report Moody's published April 17. 
  • 20 drugs have been in shortage for nearly 8 years: ASHP

    Since 2015, at least 20 drugs have been in and out of shortage, according to the American Society of Health-System Pharmacists' drug supply database. 
  • BCBS Texas deploys mobile pharmacy benefits app

    Blue Cross and Blue Shield of Texas announced the launch of a mobile pharmacy benefit app, "MyBlueRxTX."
  • Mark Cuban Cost Plus Drugs taps partner for pharmacy payment

    One day after launching a network of independent pharmacies across four states, Mark Cuban Cost Plus Drug Co. tapped RevSpring to handle the drug company's payments. 
  • FDA only inspected 6% of foreign drug manufacturers in 2022: Report

    With the exception of critical cases, during the coronavirus pandemic the FDA mostly halted the inspections of overseas drug manufacturing sites. Now, long after they have resumed, the FDA is still very much behind schedule. In 2022, the agency only inspected 6 percent of overseas facilities, according to an investigation from ProPublica.
  • CDC recommends 2nd bivalent booster for seniors, immunocompromised

    The CDC backed changes to the COVID-19 vaccination schedule on April 19, simplifying recommendations and including a second bivalent booster authorized by the FDA April 18 for senior populations and people who are immunocompromised.
  • HHS unveils COVID-19 care plan for uninsured as PHE nears expiration

    HHS released a COVID-19 vaccine and treatment access program April 18 in anticipation of the end of the pandemic's public health emergency, which is expected to expire May 11. 
  • More hospitals target pharmacy staff burnout

    As more pharmacy employees report burnout, 84 percent of hospitals are working to reverse the growing trend, according to a national study conducted by the American Society of Health-System Pharmacists.
  • A unique Ozempic side effect: Weird dreams

    Many people taking popular weight loss drugs such as Ozempic and Wegovy are reporting an unexpected side effect: having bizarre and vivid dreams, The Wall Street Journal reported April 18. 
  • Mark Cuban builds a pharmacy network

    Mark Cuban is creating an independent pharmacy network to "serve patients more widely" after pitching the idea to local pharmacy owners in February. 

Featured Whitepapers

Featured Webinars

>